SciSparc Ltd. (SPRC)

NASDAQ: SPRC · Real-Time Price · USD
0.238
+0.001 (0.42%)
At close: Nov 20, 2024, 4:00 PM
0.235
-0.003 (-1.39%)
After-hours: Nov 20, 2024, 5:30 PM EST
0.42%
Market Cap 853.85K
Revenue (ttm) 1.75M
Net Income (ttm) -5.68M
Shares Out 3.59M
EPS (ttm) -5.01
PE Ratio n/a
Forward PE 0.01
Dividend n/a
Ex-Dividend Date n/a
Volume 49,922
Open 0.235
Previous Close 0.237
Day's Range 0.232 - 0.239
52-Week Range 0.206 - 14.220
Beta 1.04
Analysts n/a
Price Target n/a
Earnings Date Dec 3, 2024

About SPRC

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in sof... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 3
Stock Exchange NASDAQ
Ticker Symbol SPRC
Full Company Profile

Financial Performance

In 2023, SciSparc's revenue was $2.88 million, an increase of 113.73% compared to the previous year's $1.35 million. Losses were -$5.12 million, 97.6% more than in 2022.

Financial Statements

News

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

FDA confirm s that SciSparc's study may proceed only a month after application submission

7 weeks ago - GlobeNewsWire

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

The intended selling valuation represents an increase of 47 % from the valuation at the time of SciSparc's initial investment in MitoCareX Bio

7 weeks ago - GlobeNewsWire

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

FDA confirm s that SciSparc's study may proceed following the application submission a month ago

2 months ago - GlobeNewsWire

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel will take part in the trial

2 months ago - GlobeNewsWire

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.

2 months ago - GlobeNewsWire

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto

2 months ago - GlobeNewsWire

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.

2 months ago - GlobeNewsWire

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t...

2 months ago - GlobeNewsWire

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees of approximately $3 million in cash

3 months ago - GlobeNewsWire

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel

3 months ago - GlobeNewsWire

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center , Jerusalem , Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of...

3 months ago - GlobeNewsWire

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

The clinical trial for SCI-210 is conducted in Israel, after which the Company aims to move forward with the commercialization process of SCI-210, first in the Israeli market

3 months ago - GlobeNewsWire

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

Friday, SciSparc Ltd. SPRC signed an exclusive patent license agreement with Polyrizon Ltd to out-license its SCI-160 program to treat pain.

3 months ago - Benzinga

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met

3 months ago - GlobeNewsWire

SciSparc Updates Regarding the Status of the AutoMax Merger

SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court's approval of AutoMax's petition to convene special class meetings of its shar...

3 months ago - GlobeNewsWire

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI

3 months ago - GlobeNewsWire

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors

4 months ago - GlobeNewsWire

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

SciSparc will receive additional payments and execution fees if certain milestones are met

4 months ago - GlobeNewsWire

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare...

4 months ago - GlobeNewsWire

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t...

4 months ago - GlobeNewsWire

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

According to the agreement, SciSparc's pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “...

4 months ago - GlobeNewsWire

SciSparc Secures Strategic Advantage with Grant of European Patent

TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to...

6 months ago - GlobeNewsWire

Action Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental Health

WASHINGTON--(BUSINESS WIRE)--New research provides resources for increasing 988 usage and access among populations disproportionately impacted by suicide and their loved ones.

6 months ago - Business Wire

SciSparc to Acquire AutoMax

TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...

7 months ago - GlobeNewsWire

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...

8 months ago - GlobeNewsWire